share_log

先瑞达医疗-B(06669)收到国药监对冠状动脉微导管Vericor-S2的注册批准

Zhitong Finance ·  Jan 21 08:43

先瑞达医疗-B(06669)公布,于2025年1月20日,集团收到中国国家药品监督...

智通财经APP讯,先瑞达医疗-B(06669)公布,于2025年1月20日,集团收到中国国家药品监督管理局对冠状动脉微导管Vericor-S2的注册批准。该产品适用于冠脉血管经皮介入手术中,针对狭窄血管病变部位,引导导丝穿通病变,为更换导丝和传输生理盐水或造影剂提供通道。冠状动脉微导管Vericor-S2具有卓越的通过性,跟随性与推送性,能够帮助其在狭窄病变、迂曲与细小血管中穿行无阻。公司将适时在中国开展营销活动。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 303

Recommended

Write a comment

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.